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SUMMARY | Here, we provide evidence for a detrimental role of tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) in neural death in T cell-induced experimental autoimmune encephalomyelitis 
(EAE), an animal model of multiple sclerosis (MS). Clinical severity and neuronal apoptosis in brainstem 
motor areas were substantially reduced upon brain-specific blockade of TRAIL after induction of EAE 
through adoptive transfer of encephalitogenic T cells. Furthermore, TRAIL-deficient myelin-specific 
lymphocytes showed reduced encephalitogenicity when transferred to wild-type mice. Conversely, 
intracerebral delivery of TRAIL to animals with EAE increased clinical deficits, while naive mice were not 
susceptible to TRAIL. Using organotypic slice cultures as a model for living brain tissue, we found that 
neurons were susceptible to TRAIL-mediated injury induced by encephalitogenic T cells. Thus, in addition 




Multiple sclerosis (MS) is a multiphasic 
autoimmune disease of the CNS [51] in which 
myelin-specific CD4+ Th1 cells are thought to 
orchestrate the effector processes resulting in the 
destruction of the myelin sheath [6]. Recent 
studies in MS and its animal model, experimental 
autoimmune encephalomyelitis (EAE), suggest, 
however, that already during the early phase of 
inflammation, neuronal pathology involving 
axonal transection plays a pivotal role in disease 
pathology [15, 22, 33, 52]. It has become evident 
that long-term disability in MS correlates better 
with axonal damage than with the degree of 
demyelination [4]. In the EAE model, we have 
recently reported the occurrence of apoptotic 
neurons in the brainstem of affected animals, 
indicating irreversible neuronal cell loss [11]. 
However, the mechanisms of this neuronal 
damage have to be elucidated, as they constitute 
one of the main targets in the prevention of 
persisting clinical deficits during autoimmune 
neuroinflammation [61]. 
Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL), also known as Apo2 
ligand, is a member of the TNF/nerve growth 
factor (NGF) superfamily [40, 58]. In humans, four 
membrane bound receptors for TRAIL have so far 
been identified. Of these, only TRAIL receptor 1 
(TRAIL-R1 or death receptor 4 [DR4]) [38] and 
TRAIL receptor 2 (TRAIL-R2, TRICK2, KILLER, DR5) 
[54] have the capacity to induce caspase-
dependent apoptotic cell death, whereas TRAIL-R3 
(DcR1) and TRAIL-R4 (DcR2) lack a functional death 
domain and are considered to act as decoy 
receptors [9, 10]. In the murine system, two decoy 
receptors have been reported recently [46], 
whereas only one death-mediating TRAIL receptor 
is known, which has the highest homology with 
the human TRAIL receptor 2 [59]. 
Initial reports indicated a specific and selective 
action of TRAIL on transformed cells [3, 55]. They 
also provided evidence for the role of TRAIL in the 
immunosurveillance of tumor cells [7, 48]. 
Expression of TRAIL has been shown for a variety 
of immune cells, and T cells were found to 
upregulate TRAIL upon antigen-specific 
stimulation [30, 57]. Systemic (intraperitoneal) 
injection of soluble neutralizing TRAIL-R2 (DR5) 
leads to exacerbation of murine collagen-induced 
arthritis [49], autoimmune diabetes [23], and 
myelin oligodendrocyte glycoprotein (MOG)-
mediated EAE in C57BL/6 mice [20]. Moreover, 
recent reports have discussed the possible 
contribution of TRAIL to selection processes within 
the thymus [8, 24]. We have even shown that 
TRAIL is capable of inhibiting T cell activity and is 
upregulated in MS patients responding to 
interferon- β therapy [28, 56]. 
Further research has revealed that TRAIL is also 
able to induce apoptosis in nontransformed to 
normal human (but not murine) hepatocytes [21];
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human endothelial cells [27]; and human 
erythropoietic cells in vitro [60]. In the brain, 
isolated human oligodendrocytes and human 
brain cells preserved in slice cultures were shown 
to be susceptible to TRAIL [32, 35]. These findings 
suggest that TRAIL has an ambivalent role in 
inflammation by promoting anti-inflammatory 
mechanisms on the one hand, and by a 
destructive effector function on the other hand. 
We therefore hypothesized that TRAIL acts as a 
mediator of brain cell death during autoimmune 
inflammatory CNS damage. Our experiments 
involving targeted inhibition of TRAIL in the brain 
and TRAIL-deficient mice show that the death 
ligand TRAIL indeed contributes to T cell-induced 




Targeted Modulation of TRAIL in the CNS 
In view of the existing literature, we hypothesized 
that TRAIL, apart from its reported anti-
inflammatory properties, contributes to the 
damage mechanisms in EAE. In order to modulate 
TRAIL function selectively within the brain, we 
injected human TRAIL receptor 2 (TRAIL-R2; DR5) 
fused to human Fc (DR5:Fc, 1 μg in 10 μl) 
intracisternally (i.c.) at three time points after the 
adoptive transfer of encephalitogenic 
lymphocytes inducing EAE. This DR5:Fc fusion 
protein has been shown to recognize mouse 
TRAIL [45], and it protects glioma cells [13] and 
murine fibroblasts from TRAIL-mediated 
apoptosis in vitro (O.A. and F.Z., unpublished 
data). Indeed, DR5:Fc-treated mice showed 
markedly decreased clinical signs, as compared to 
PBS-injected control animals (►Fig. 1A), over a 
prolonged observation period [F12–80(1, 68) = 7.6; p 
< 0.05, ANOVA; n = 5 for DR5:Fc; n = 6 for PBS 
control group]. However, we were concerned 
about a possible nonspecific effect of the Fc 
portion of the DR5:Fc molecule used in this 
experiment. We therefore repeated this 
experiment using the corresponding human Fc 
protein alone as a control for DR5:Fc and were 
able to confirm our findings, as DR5:Fc-treated 
animals showed reduced disease scores (►Fig. 1B) 
[*F11–20(1, 10) = 5.0; p < 0.05, ANOVA; n = 8 for both 
groups]. A time course analysis (2, 6, and 12 hr) 
showed distribution of intracisternally injected 
DR5:Fc throughout the brain and spinal cord 
(►Fig. 1C). 
 
Effects of Intracerebral DR5:FC Injections on Immune 
Cells in the Brain and outside the Brain 
We realized that animals receiving DR5:Fc showed 
a slightly earlier disease onset, suggesting a 
possible systemic immunoregulatory impact of 
the intracisternally applied DR5:Fc, as previously 
shown by others [20]. Therefore, we recovered T 
cells and macrophages/microglia cells from the 
brains of SJL animals transferred with 
encephalitogenic T cells and treated with three 
intracisternal injections of DR5:Fc or Fc alone. We 
found that, at the very onset of the disease (day 7 
posttransfer), in the DR5:Fc-treated animals even 
more T cells expressed the activation marker CD25 
(►Fig. 2A). After the peak of the disease, no 
differences in the activity of the T cells were 
further observed. Absolute numbers and 
proportion of T cells and macrophages/microglia 
cells were comparable at both time points: at 
disease onset, the mean total number of 
infiltrating cells per mouse (± SEM) was 3.2 × 106 ± 
1.6 for Fc-treated animals and 2.7 × 106 ± 1.4 for 
DR5:Fc-treated animals (n = 4 for both groups; p > 
0.05, Mann-Whitney U test). After disease peak, the 
mean total number of infiltrating cells per mouse 
(±SEM) was 2.0 × 106 ± 0.8 for Fc-treated animals 
(n = 6) and 2.5 × 106 ± 1.1 for DR5:Fc-treated 
animals (n = 5; p > 0.05, Mann-Whitney U test). In a 
similar experiment, CNS-draining deep cervical 
lymph node cells, as well as splenocytes, were 
isolated at day 11 posttransfer and checked for 
antigen-specific proliferation and cytokine profiles 
(IFN-γ and IL-4). However, analysis of these 
parameters revealed neither a systemic effect of 
DR5:Fc treatment on lymphocyte proliferation nor 
cytokine synthesis in lymphocytes from deep 
lymph nodes or in splenocytes (►Fig. 2B). We next 
investigated the body distribution of 
intracisternally applied DR5:Fc. This was possible 
by detection of the human Fc fragment contained 
in this recombinant molecule. We found this 
fusion protein diffusely distributed in the 
brainstem up to a maximum of 2 hr after 
intracisternal application. At that time point, we 
detected DR5:Fc confined to macrophage-like 
cells in deep cervical lymph nodes, but not 
diffusely distributed. After no sooner than 6 hr, we 
found DR5:Fc-containing macrophage-like cells 
prominently in the spleen (►Fig. 2C). A similar 
distribution was found with control Fc injection 
alone indicating unspecific uptake of DR5:Fc into 
phagocytes, which would rule out a systemic 
distribution of soluble DR5:Fc. 
 
Attenuated Passive EAF upon Transfer of TRAIL-
Deficient T Cells 
Our data so far suggested that TRAIL plays a 
detrimental role in effector mechanisms occurring 
during neuroinflammation within the CNS. In view 
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of the pivotal role of encephalitogenic T 
lymphocytes in both initiation of disease and 
tissue damage [16], we considered that infiltrating 
myelin-specific T lymphocytes might employ 
TRAIL as an effector molecule. We therefore 
immunized TRAIL-deficient mice [47] or wild-type 
C57BL/6 littermates with MOG peptide 35-55 
(MOG35-55) and obtained MOG-reactive 
lymphocytes. In MOG-immunized TRAIL-deficient 
mice, we found an increased number of CD25+ T 
cells in draining lymph nodes on day 13 as 
compared to wild-type (mean percentage ± SEM 
was 64.8% ± 1.6 for TRAIL-deficient animals versus 
51.5% ± 1.4 for wild-type littermates; p < 0.05, 
Mann-Whitney U test; n = 5 per group), whereas 
no difference in CD44 expression and proliferation 
was observed. Thus, there are indications of an 
increased activation of T cells in TRAIL-deficient 
animals. Subsequently, we transferred these cells 
upon antigen-specific restimulation into wild-type 
C57BL/6 littermates. In this setting, we were able 
to closely investigate the roles of TRAIL outside 
and within the CNS, as the immunomodulatory 
function of TRAIL was preserved in the wild-type 
recipients. In fact, these TRAIL-deficient 
lymphocytes showed a significantly reduced 
capacity to induce EAE: disease manifestation and 
mean clinical scores (►Fig. 3) were significantly 
milder in mice receiving TRAIL-deficient cells (EAE 
incidence: 1 out of 7), compared to recipients of 
wild-type cells [EAE incidence, 9 out of 11; 
comparison of mean clinical scores, F10–49(1, 40) = 
4.9; p < 0.05]. 
 
Reduced CNS Damage upon Intracisternal DR5:Fc 
Injection 
The clinical and immunological data so far 
suggested a striking effect of intracisternal DR5:Fc 
application: although the peripheral antigen 
response was not altered, DR5:Fc-receiving 
animals showed a favorable outcome after the 
disease peak. We then addressed the question of 
whether intracisternal DR5:Fc modulates the 
inflammatory infiltration within the CNS. However, 
we were unable to find a difference, as we 
observed a comparable number of inflammatory 
foci/section corrected for focus size (2.4 ± 0.4 in 
the DR5:Fc-treated versus 2.5 ± 0.6 in the Fc-
treated control animals, counted and calculated in 
four sections per mouse of three mice from each 
group in a blinded manner; p > 0.05, Mann-
Whitney U test) [2]. Thus, we assumed that 
intracisternal DR5:Fc may have an impact on the 
tissue damage pattern. Indeed, 
immunohistochemical staining for activated 
caspase 3, a central effector enzyme involved in 
the execution of apoptotic cell death, revealed 
positive neurons with transected neurites (►Fig. 
4A). Quantitative assessment of caspase-positive 
neurons indicated a significant difference 
between DR5:Fc- or vehicle-treated animals (►Fig. 
4B). Further, we quantified the caspase-positive 
oligodendrocytes in a blinded fashion in the same 
way as the neurons. We also found a reduced 
number of caspase-positive oligodendrocytes in 
DR5:Fc-treated animals, although this difference 
showed a statistical trend only (►Fig. 4B). 
Moreover, both axonal pathology determined by 
APP staining (four longitudinal sections per mouse 
with five mice per group assessed in a blinded 
manner) and demyelination measured with Luxol 
fast blue staining (areas were assessed using a 
MicroBrightField setup; n = 5 mice per group) 
were reduced in the DR5:Fc-treated animals (►Fig. 
4C). 
 
Direct Contact between TRAIL-Expressing Immune 
Cells and Apoptotic Neurons during EAE 
Our findings so far suggest a role of TRAIL in 
contributing to tissue damage during 
autoimmune neuroinflammation. The comparable 
immune response in the periphery and 
inflammatory infiltration of the brain argued 
against a possible indirect, i.e., 
immunomodulatory, effect of intracerebral 
DR5:Fc. We therefore speculated that TRAIL, 
released by or localized to infiltrating myelin-
specific immune cells, may be responsible for 
death in TRAIL receptor-bearing target cells during 
EAE. We observed that activation of caspase 3 
throughout the cytoplasm of dying brain cells was 
indeed regularly accompanied by (1) chromatin 
condensation, as detected by hematoxylin-eosin 
counterstaining (►Fig. 4D), and (2) nuclear 
condensation and membrane blebbing, as 
detected by electron microscopy (►Fig. 4E). In 
contrast, apoptotic neurons in normal control 
mice were entirely absent. Our 
immunohistochemical analysis of normal mouse 
brain showed expression of the death-mediating 
TRAIL receptor 2 predominantly on neurons and, 
to some extent, on oligodendrocytes (►Fig. 5A-
5D). Importantly, in the course of EAE, we detected 
TRAIL-positive lymphocytes that had invaded the 
brain in close vicinity and direct contact with 
neurons showing the appearance of caspase 3 
activation in their cytoplasm (►Fig. 4F and 4G). 
These data suggest that brain-infiltrating and 
TRAIL-expressing lymphocytes are able to deliver 
an apoptosis-inducing signal to receptor-bearing 
neurons in the course of neuroinflammation. 
 
Regulation of Intracerebral Expression of TRAIL 
Receptor 2 and TRAIL in the Course of EAE 
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In order to confirm the role of TRAIL in the 
induction of neuronal apoptosis in vivo, we 
injected recombinant TRAIL into the 
compartment containing the cerebrospinal fluid. 
However, even repeated intracisternal injections 
of recombinant preparations of multimerized 
human TRAIL induced neither clinical disability 
nor apoptosis of neurons and oligodendrocytes, 
respectively, in healthy SJL mice (►Fig. 6A). In 
contrast, the same TRAIL preparations were 
effective in killing mouse fibroblasts (O.A. and F.Z., 
unpublished data). We therefore assumed that 
susceptibility to TRAIL-mediated cell death is 
differentially regulated in normal and inflamed 
murine brain tissue. Supporting this idea, 
quantitative gene expression analysis showed 
that both the death-mediating TRAIL receptor 2 
and TRAIL itself are significantly upregulated in 
the CNS during EAE (►Fig. 6B and 6D). Further, 
analysis of protein expression on neurons (►Fig. 
5A-5D) revealed a significant increase of TRAIL-R2 
in passive EAE (both in Fc-injected animals and 
animals treated with DR5:Fc in order to block 
TRAIL signaling) (►Fig. 6C). Thus, we decided to 
test intracisternal TRAIL in the course of the 
inflammatory EAE paradigm. A recombinant TRAIL 
preparation containing a FLAG tag was injected 
together with an enhancer anti-FLAG antibody for 
multimerization (►Fig. 6E). Indeed, as compared 
to injection of the enhancer alone, application of 
TRAIL prior to and at the onset of EAE significantly 
increased EAE severity [►Fig. 6E and 6F; F9–47(1, 
20) = 6.7; p < 0.05 for comparison of clinical 
scores, ANOVA; n = 5 for both groups]. Moreover, 
considering reports on diverging cytotoxic 
capacities of different TRAIL preparations [25, 41], 
we tested and confirmed this finding (O.A., R. 
Lauster, and F.Z., unpublished data) using a 
recombinant TRAIL preparation that is active 
without any enhancing antibodies, i.e., N-terminal 
truncated human TRAIL (residues 95–281) 
containing an N-terminal 6-His tag [2]. These 
results provide evidence that, during EAE, TRAIL 
mediates cell death in the CNS via its specific 
receptors, which are upregulated under these 
inflammatory conditions. 
 
TRAIL-Mediated Neurotoxicity of Encephalitogenic T 
Cells In Vitro 
In a final set of experiments, we assessed the role 
of TRAIL as a mediator of neuronal cell death by 
encephalitogenic lymphocytes in living 
organotypic brain slices. PLP-specific activated 
lymphocytes used to induce transfer EAE were 
stained with carboxyfluorescein diacetate (CFDA) 
and applied to the surface of these brain slices 
[18]. Cell death was visualized by propidium 
iodide (PI) staining (►Fig. 7A). N-methyl-D-
aspartate (NMDA)-induced damage in the 
pyramidal cell layer of the cornu ammonis (CA) 
and granule cell layer of the dentate gyrus (DG) 
was performed as a positive control. The number 
of PI+ cells in the neuronal layer of the CA and DG 
(for quantification, see [53]) induced by PLP-
restimulated lymphocytes was significantly 
reduced in the presence of DR5:Fc(1 μg/ml), as 
compared to their number in the presence of Fc 
alone (►Fig. 7A and 7B). In addition, we employed 
TRAIL-deficient T cells and observed significantly 
reduced neuronal cell death when compared to 
wild-type T cells (►Fig. 7C). In further confocal 
studies, we identified invading CFDA-labeled T 
cells in the vicinity of dead neurons whose DNA 
was stained by PI (►Fig. 7D). Importantly, 
immunolabeling of TRAIL detected by PerCP-Cy5.5 
fluorescence was confined to sites surrounding 
these invaded T cells and dying neurons (►Fig. 
7D). These results suggest that both soluble and 
lymphocyte bound TRAIL may contribute to 
neuronal death in the brain. 
 
Discussion 
Following a series of recent findings [11, 15, 22, 33, 
39, 52], neuronal pathology is now considered to 
be a key feature of autoimmune 
neuroinflammation, namely EAE and MS. However, 
the precise mechanisms leading to the destruction 
of neurons during the myelin-specific immune 
attack have yet to be elucidated. 
The death ligand TRAIL has primarily aroused 
tremendous interest due to its ostensible 
selectivity in killing tumor cells, as observed in 
various animal models [3, 7, 48, 55]. Later, several 
studies including our own work [28, 56, 57] have 
demonstrated the immunomodulatory capacity of 
TRAIL in the immune system. Importantly, the 
blockade of TRAIL action outside the CNS results 
in the exacerbation of various autoimmune 
disease models [23, 49] including EAE [20]. These 
studies propose the potentially therapeutic use of 
TRAIL as a protective agent for autoimmunity. 
Surprisingly, it became clear that, apart from these 
immunomodulatory functions, TRAIL may act as a 
death-inducing effector molecule on 
nontransformed human cells: certain TRAIL 
preparations were found to have toxic effects on 
hepatocytes as well as brain cells [21, 32, 35]. Since 
we could show that TRAIL is upregulated by 
activated human lymphocytes [13, 57], we 
speculated about a potential role of TRAIL in the 
course of the immune cell attack to the brain. With 
these aspects of TRAIL biology in mind, we 
employed strategies for a selective blockade of 
TRAIL within the CNS, which is an anatomically 
and immunologically separate compartment. In 
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fact, in contrast to systemic application of soluble 
TRAIL receptor molecules outside the brain [20], 
DR5:Fc injection selectively into this compartment 
resulted in an amelioration of EAE. We were able 
to show that our intracisternal route of injection 
did not influence the peripheral immune response 
including T cell proliferation and cytokine release. 
Furthermore, transfer of myelin-specific TRAIL-
deficient T cells into wild-type recipients yielded a 
significantly attenuated disease score. In this 
experimental setting, the peripheral 
immunomodulatory role of TRAIL was preserved, 
as recipient wild-type animals were still able to 
regulate the transferred T cells via TRAIL. These 
findings indicate that brain-invading myelin-
specific T cells [16] that lack the important effector 
molecule TRAIL are significantly reduced in their 
damaging capacity. An initial increase in T cell 
activity in the brain following CNS-specific 
blockade of TRAIL signaling is in line with the anti-
inflammatory capacity of TRAIL as earlier reported 
for the peripheral immune system [20, 28, 56]. We 
conclude that TRAIL plays an ambivalent role 
during EAE: extracerebrally, i.e., within the 
peripheral immune system, TRAIL has an anti-
inflammatory (and thus protective) effect, 
whereas in the central nervous system this anti-
inflammatory effect is less important for EAE 
outcome than the apoptosis-inducing effector 
function targeting neural cells. 
Our analysis of healthy CNS tissue revealed that 
main targets during neuroinflammation, i.e., 
neurons and oligodendrocytes, express the death-
mediating TRAIL receptor 2 [12]. In contrast, TRAIL 
itself is not expressed within the brain [12]. 
Indeed, soluble TRAIL, when applied to living CNS 
tissue [35] or oligodendrocytes [32], can induce 
caspase-dependent brain cell death. Thus, it may 
well be the case that TRAIL-expressing activated T 
cells that invade the brain during 
neuroinflammation [16] mediate brain damage 
using TRAIL as an effector molecule. In fact, we 
observed that caspase-dependent neuronal cell 
death in the course of EAE [11] was significantly 
reduced by blocking TRAIL within the CNS as 
shown by our present data. In our study, caspase-
positive neurons were frequently contacted by 
small, TRAIL-expressing lymphocytes, favoring T 
cells as the cellular source of TRAIL. 
We and other investigators have previously 
shown that (1) TRAIL is upregulated on the surface 
of T cells upon antigen-specific stimulation [30, 
57], (2) TRAIL is secreted by activated T cells [31], 
and (3) TRAIL plays a significant role in T cellular 
cytotoxicity [13]. Our in vitro studies using 
organotypic slices show that myelin-specific T 
cells invading organotypic slice cultures release 
TRAIL in the vicinity of dying neurons. In fact, 
these encephalitogenic T cells are able to induce 
substantial neuronal damage. This is in line with 
recent reports by Giuliani et al. reporting a marked 
toxicity of human T cells toward human neurons in 
vitro [19]. In the present study, activated TRAIL-
deficient lymphocytes from knockout animals 
showed a significant reduction in their killing 
capacity. Using 2-photon laser scanning 
microscopy for live imaging in slices [36], we 
recently observed that TRAIL-deficient T cells 
directly contact neurons but show a reduced 
neurotoxic capacity (O.A., E.P., R.N., and F.Z., 
unpublished data). Moreover, functional blockade 
of TRAIL using DR5:Fc was effective in preventing 
this neuronal cell death, indicating a pivotal role of 
TRAIL in damage processes. However, it is possible 
that TRAIL secreted by infiltrating macrophages 
may contribute to TRAIL-mediated neural damage 
in EAE, as we recently identified activated 
macrophages as a significant source of soluble 
TRAIL [14]. This is supported by Miura et al., who 
have demonstrated the involvement of the TRAIL 
system in macrophage-mediated neuronal cell 
death occurring in a humanized mouse model of 
HIV-associated encephalopathy in vivo [34]. 
Interestingly, we could not discern any cytotoxic 
effects in connection with either of two different 
TRAIL preparations applied intracisternally in 
healthy animals. This observation is in line with a 
previous report demonstrating that intracerebral 
injection of TRAIL in a xenograft brain tumor 
model only affects the tumor cells and does not 
show significant neurotoxicity to the normal CNS 
tissue [43]. However, a recent report showed that 
TRAIL, which lacks any hepatotoxicity in healthy 
rodents, critically contributes to hepatocyte cell 
death in different models of murine hepatitis [62]. 
We therefore performed quantitative expression 
analysis for TRAIL receptor 2 and found a 
significant upregulation prior to and during the 
peak phase of EAE. Accordingly, we observed that 
intracisternally applied soluble TRAIL enhanced 
disease severity in animals with ongoing EAE, 
while healthy animals were not affected. This 
indicates that receptor levels under normal 
conditions are not sufficient to mediate a 
significant death signal, which is only achieved in 
the course of inflammation. Indeed, inflammation 
itself was not modulated by intracerebral TRAIL 
blockade, and this further corroborates the idea 
that TRAIL is a specific death-inducing effector 
molecule in the brain. This finding might also 
explain why the use of TRAIL for tumor therapy 
did not result in toxic effects to healthy neurons. 
Taken together, our study reveals that the death 
ligand TRAIL critically contributes to irreversible 
CNS damage during autoimmune 
neuroinflammation. Evidence is provided for an 
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important role of TRAIL expressed on and 
secreted by CNS-invading lymphocytes in the 
effector phase of a multiple sclerosis animal 
model. One has to bear in mind, however, that the 
immunosuppressive properties of TRAIL may be 
useful to enhance the effects of TRAIL outside the 
CNS. This complex action of TRAIL resembles a 
double-edged sword, as known for other 
members of the TNF family such as the CD95 
system [63]. However, targeted modulation of 
TRAIL receptor-TRAIL interactions within the 
inflamed brain may represent a possible 
therapeutic strategy for the prevention of 




Reverse Transcriptase PCR 
Total RNA was isolated from PBS-perfused frozen 
tissue followed by digestion with DNase I. PCR 
conditions were as follows: 30 cycles, 30 s/95°C, 30 
s/65°C, 45 s/72°C; TRAIL-R2 primer sequences 
(GenBank AF176833) 5′-CACAAATACGGTGTGTC-
GATG-3′ (nucleotides 372–392) and 5′-
CTGGAACCAGGAGTCCTATCC-3′ (nucleotides 551-
571); TRAIL primer sequences (Genbank 
NM009425) 5′-TGAGGATTTCTGGGACTCCACTGA-
3′ (nucleotides 241–264) and 5′-CTTCAGCTTCCT-
GAAATCGG-3′ (nucleotides 628–647); β-actin 
primer sequences (GenBank J04181) 5′-
GTGGGCCGCCCTAGGCACCA-3′ (nucleotides 165–
184) and 5′-CGGTTGGCCTTAGGGTTCAGGGGG-3′ 
(nucleotides 386–409). Isolated PCR fragments 
were reamplified and checked with an ABI 377 
DNA sequencing system (Applied Biosystems, 
Weiterstadt, Germany). 
 
Quantitative Real-Time PCR 
For quantitative real-time PCR, reverse 
transcription and Taqman real-time PCR analysis 
was done in duplicate using the 2-ΔΔCT relative 
quantification method (ABI-Prism 7700, Applied 
Biosystems). PCR conditions: 2 min at 50°C, 10 min 
at 95°C, followed by 40 cycles, 15 s/95°C, 60 
s/60°C. The following PCR primers and fluorogenic 
probes (Eurogentec, Seraing, Belgium; designed 
with Primer Express Software, Applied Biosystems) 
were used: TRAIL forward, 5′-GATCACTC 
GGAGAAGCAACTCA-3′; TRAIL reverse, 5′-GAGA 
GGAC-TCCCAGGATTCAATC-3′; TRAIL probe, 5′-
FAMCAATCTCCAAGGATGGAAAGACCTTAGGCCA -
TAMRA-3′; TRAIL-R2 forward, 5′-TGCAAACCAGGC 
ACCTTTG-3′; TRAIL-R2 reverse, 5′-TCT-TCCCCGTC 
AGTGCAGTT-3′; TRAIL-R2 probe, 5′-FAM-AGACTCC 
CCTGAGATC-TGCCAGTCATGCT-TAMRA-3′; GAPDH 
forward, 5′-CTCAACTACATGGTCTACAT-GTTCCA-
3′; GAPDH reverse, 5′-CCATTCTCGGCCTTGACTGT-




PBS-perfused frozen tissue or lymphocytes were 
homogenized in extraction buffer containing 1% 
Triton X-100 and protease inhibitors (0.2 mM 
PMSF, 1 μg/ml pepstatin, 0.5 μg/ml leupeptin). 
Samples were separated by 12% SDS-PAGE, 
membranes were incubated with anti-TRAIL-R2 
antibodies (dilution 1:1000; AB1687 or AB16942; 
Chemicon, Temecula, CA). Antibodies coupled to 
horseradish peroxidase (Dako Diagnostica, 
Hamburg, Germany) were used as secondary 
antibodies, and an ECL-plus system (Amersham 
Pharmacia, Freiburg, Germany) was used for 
development. Membranes were sequentially 
incubated with an antibody against β-actin 
(Sigma, Deisenhofen, Germany). 
 
Histology and Immunohistochemistry 
Mice euthanized with narcotics were transcardially 
perfused with 4% paraformaldehyde (PFA). 
Horizontal 50 μm thick vibratome sections 
(Shandon, Pittsburgh, PA) or 10 μm thick paraffin 
sections were immersed with 3% H2O2 to quench 
unspecific endogenous peroxidase activity, then 
washed and blocked (10% normal serum and 0.5% 
Triton X-100) prior to overnight incubation with 
anti-activated caspase 3 (1:100; R&D, Wiesbaden, 
Germany), anti-TRAIL-R2 antibody (Ab16942; 1:50; 
Chemicon), or anti-β-APP (1:1000; Zymed 
Laboratories, San Francisco, CA). Sections were 
immunostained using FITC-labeled secondary 
antibodies or the avidin:biotinylated enzyme 
complex technique (ABC-Elite, Vector 
Laboratories, Burlingame, CA) before 
development with diaminobenzidine ([DAB]; 
brown signal) as a substrate. Ig-control 
experiments were performed for all primary 
antibodies, and no staining was observed under 
these conditions. Axonal ovoids indicating 
transection [2] were counted in longitudinal spinal 
cord sections (cervical to lumbosacral level; five 
sections per mouse). Areas of demyelination were 
quantitatively evaluated using Luxol fast blue 
staining (American Histolabs, Gaithersburg, MD). 
Cell-specific expression of TRAIL-R2 was assessed 
as immunofluorescence signal intensity on 
vibratome sections using a MetaMorph analysis 
setup. For counterstaining of nuclei, brainstem 
sections stained for active caspase 3 were 
incubated with Harris hematoxylin for 1 min at 
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room temperature. For the staining of TRAIL, 
these sections were labeled with mouse 
DR5:human Fc chimera (1:25; R&D) and visualized 
using DAB/Ni as a chromogen (dark blue/black 
signal), as described elsewhere [26]. Electron 
microscopy was performed on a Zeiss EM 900 
(Jena, Germany). 
 
Induction of Active and Passive EAE, Treatment 
Procedures, and Distribution Analysis 
For adoptive transfer (passive) EAE in SJL mice, 
female donors (6–8 weeks; Harlan, Rehovot, Israel; 
Charles River, Sulzfeld, Germany) were immunized 
with murine PLP139-151 (purity > 95%; 
Pepceuticals, Leicester, UK) as previously 
described [50]. Primary lymph node cells were 
prepared 10 days later, restimulated with PLP139-
151 (10 μg/ml) for 4 days, and injected 
intravenously (i.v.) into syngenic recipients (3 × 
107 cells per mouse). Antigen specificity of 
injected cells was routinely checked with a 
standard 3[H]-thymidine proliferation assay. For 
active EAE in SJL mice, animals were immunized 
as previously described [1, 2] with the following 
modifications: each mouse received 100 μg 
PLP139-151 in complete Freund adjuvant (CFA; 
supplemented with M. tuberculosis H37Ra, 2 
mg/ml), and pertussis toxin (200 ng per mouse; 
List) was injected intraperitoneally at days 0 and 2 
after immunization. The control group for serial 
assessment of gene expression in the course of 
active EAE (►Fig. 6B and 6D) was sham 
immunized, i.e., using the same immunization 
protocol as for active EAE, including pertussis 
toxin injections, but without PLP139-151. For 
passive EAE in TRAIL-deficient animals, C57BL/6 
TRAIL knockout mice (kindly provided by Amgen, 
Seattle, WA) [7, 47] and wild-type littermates were 
immunized with MOG35-55 (purity >95%; 
Pepceuticals; in CFA supplemented with M. 
tuberculosis H37Ra, 4 mg/ml). Twelve days later, 
animals were sacrificed, whereupon draining 
lymph node cells were isolated, restimulated with 
MOG35-55 (30 μg/ml) in the presence of IL-12 (20 
ng/ml, R&D), harvested after 72 hr, and injected 
into wild-type recipients (20 × 106 blasts per 
mouse). Pertussis toxin (400 ng per mouse) was 
administered at day 0 and 2 after immunization. 
For all EAE procedures, neurological deficits were 
graded as previously described [1]. For 
intracisternal treatment procedures, mice were 
intravenously anesthetized with ketamine (50 
mg/kg; Curamed, Karlsruhe, Germany) and 
xylazine (10 mg/kg; Bayer, Leverkusen, Germany) 
before puncture of the cisterna magna with a 26G 
syringe (Hamilton, Bonaduz, Switzerland). Human 
recombinant DR5:Fc (1 μg per mouse) or vehicle 
control (1 μg human Fc for ►Fig. 1B or PBS alone 
for ►Fig. 1A; see text and figures for explanation) 
was injected in a volume of 10 μl [37, 42, 44]. 
Human Fc fragment was obtained from 
Calbiochem (San Diego, CA) and dialyzed against 
sterile PBS before use. Similarly, recombinant 
human TRAIL (400 ng with 2 μg enhancer 
antibody for multimerization per mouse; Alexis, 
San Diego, CA) or vehicle control (enhancer 
antibody alone) was injected intracisternally in a 
total volume of 10 μl. Distribution of DR5:Fc or Fc 
was assessed in sections of brain, lymph nodes, 
and spleen using anti-human Fc fragment 
antibody (Sigma) and FITC or ABC/DAB for 
visualization. TRAIL was visualized using a DR5:Fc-
FITC detection system (Alexis). All procedures 
were conducted according to protocols approved 
by the local animal welfare committees. 
 
Isolation of CNS Mononuclear Cells and FACS 
Analysis 
Isolation of CNS mononuclear cells was performed 
basically as previously described [17, 29], with 
minor adaptations: tissue digestion was 
performed in DMEM containing 363 U/ml 
clostridiopeptidase A (Sigma) and 200 U/ml DNase 
I (Roche, Mannheim, Germany) for 30 min at 37°C. 
Homogenate was resuspended in 23% Percoll 
(Amersham Pharmacia) and underlain with 73% 
Percoll. The gradients were centrifuged for 30 min. 
Phenotypic analysis of the infiltrate was performed 
using a FACSCalibur (Becton Dickinson, 
Heidelberg, Germany). Activation of T cells was 
monitored as described previously [36] using 
antibodies against CD3, CD25, and CD44. 
Activation of CNS-derived macrophages was 
analyzed by monitoring the expression of ICAM-1 
on nonlymphocytic CD11b-positive cells (all 
antibodies from BD Pharmingen, Heidelberg, 
Germany). 
 
Ex Vivo Proliferation 
Lymph node cells and splenocytes were isolated 
as previously described [5]. After 72 hr culture with 
PLP (5 or 25 μg/ml) or concanavalin A (ConA; 2 
μg/ml), 0.5 μCi 3[H]-thymidine was added to each 
well, and 18 hr later incorporation was measured 
in counts per minute (c.p.m.) with a Microbeta 
counter (Wallac, Freiburg, Germany). 
 
Cytokines 
For detection of IFN-γ or IL-4, sandwich ELISAs of 
supernatants were performed according to the 
manufacturer’s instructions (Becton Dickinson). 
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Coculture of Slices and T Cells 
Organotypic entorhinal-hippocampal slice 
cultures (350 μm thick) from 10-day-old SJL or 
C57BL/6 mice were prepared on a tissue chopper 
(Bachhofer, Reutlingen, Germany) and cultured as 
described [53]. For coculture, 5 × 104 
encephalitogenic lymphocytes (as used for EAE 
induction) were prelabeled with CFDA [18] and 
transferred to the surface of slices (day 7 in vitro) 
preincubated with DR5:Fc or Fc alone (both 1 
μg/ml) for 3 hr. NMDA (50 μM) was applied as a 
positive control. Encephalitogenicity of PLP-
specific lymphocytes was routinely checked by 
successful induction of adoptive transfer EAE. 
Damage in neuronal cell layers of the CA and DG 
was detected 12–24 hr later by adding 5 μg/ml PI 
(30 min at 36°C) [53] using a rhodamine filter (488 
nm/515 nm) with a dark-field inverse fluorescence 
microscope (Olympus, Tokyo, Japan). Dead 
lymphocytes were distinguished by double-
fluorescence microscopy and subtracted from the 
counts of PI+ cells within the neuronal layers of 
the slices. For resectioning, slices were immersed 
prior to the preparation of 20 μm thin horizontal 
cryostat sections. Brain slices were fixed using the 
same fixative and were treated as whole mounts 
in the same way as with vibratome sections. For 
confocal laser scanning microscopy, CFDA and PI 
were excited at 488 nm, emission of CFDA was 
detected between 510 and 560 nm, and emission 
of PI was detected between 570 nm and 625 nm. 
TRAIL was immunostained with the M19 antibody 
(Santa Cruz, CA) [12] and labeled with PerCP-Cy5.5 
fluorescence dye (excitation at 633 nm, detected 
between 680 and 710 nm) using a Leica TCS SP2 
confocal microscope (Leica, Heidelberg, 
Germany). Corresponding Ig-control experiments 
were performed, and no staining was observed 
under these conditions. 
 
Statistics 
For group comparisons, the Mann-Whitney U test 
was applied. To compare the EAE courses, 
statistical analysis of repeated measurements was 
performed by means of variance using the Fisher’s 
pairwise least significant difference test [1]. 
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►Fig.1. Autoimmune Encephalomyelitis Is Ameliorated by Intracerebral Injection of DR5:Fc 
Adoptive transfer EAE in SJL mice was induced by intravenous injection of 3 × 107 encephalitogenic PLP-
specific lymphocytes, and mean disease scores were significantly reduced by blockade of TRAIL in the 
CNS. (A) From the time of T cell transfer, mice were narcotized intravenously at the indicated intervals 
(arrowheads), received intracisternal injections of DR5:Fc (n = 5; open circles) or PBS (n = 6; filled circles), 
and were monitored for up to 80 days. Mean clinical disease scores were significantly reduced in the 
DR5:Fc-treated group during the indicated period [*F12–80(1, 68) = 7.6; p < 0.05, ANOVA]. (B) In order to 
rule out an unspecific Fc-mediated effect, mice were treated in a similar way but received either DR5:Fc or 
Fc fragment only as a control (n = 8 for both groups). Disease was significantly attenuated in DR5:Fc-
treated animals [*F11–20(1, 10) = 5.0; p < 0.05, ANOVA]. For (A) and (B), mean clinical disease scores with 
SEM are given. (C) Distribution of DR5:Fc throughout the brain and spinal cord was assessed 2, 6, and 12 
hr following injection into the cisterna cerebello-medullaris. A dispersed signal was found at 6 hr in the 
cortex, and a strong diffuse signal with the peak at 6 hr was found throughout the spinal cord. Scale bars, 
20 μm. 
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►Fig.2. Immunomodulatory Effect and Systemic Distribution of Intracisternal DR5:Fc 
(A) T cells and macrophages/microglia cells were isolated from the brain at the onset of the disease (day 
7) (mean disability score ± SEM for DR5:Fc-treated group, 2.63 ± 1.31; for Fc-treated control group, 0.75 ± 
0.38; n = 4 for both groups) and at the time of remission (day 14) (mean disability score ± SEM at the 
disease peak for DR5:Fc-treated group, 1.95 ± 0.81 [n = 5]; for Fc-treated control group, 2.92 ± 0.60 [n = 
6]). Activation markers determined by FACS analysis are given as means with SEM (open bars, treatment 
with Fc fragment only; filled bars, treatment with DR5:Fc; *p < 0.05, Mann-Whitney U test). 
(B) Spleens and draining cervical lymph nodes were harvested from animals with passive EAE at day 11 
after cell transfer. Animals had been treated with intracisternal DR5:Fc or Fc fragment only, as shown in 
►Fig. 1B. Proliferation (given as counts per minute [c.p.m.]) and cytokine synthesis were measured as 
described in the Experimental Procedures. Data are presented as means with SD, with each bar 
corresponding to four animals treated with Fc fragment only (open bars) or DR5:Fc (filled bars). 
(C) In order to check the distribution of the soluble receptor, naive SJL/J animals were intracisternally 
injected with DR5:Fc and sacrificed 2 and 6 hr later. CNS-draining deep cervical lymph nodes and spleens 
were isolated and stained for DR5:Fc by immunohistochemistry for the human Fc fragment of this 
molecule. Scale bars, 30 μm. 
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►Fig.3. Reduced Encephalitogenicity of TRAIL-Deficient Myelin-Reactive Lymphocytes 
MOG-specific lymphocytes from either TRAIL-deficient (ko) or wild-type (wt) donors were transferred into 
wild-type recipients. Disease was significantly milder in mice receiving TRAIL-deficient cells (filled 
squares; n = 7), compared to recipients of wild-type cells [open squares; n = 11; comparison of mean 
clinical scores, F10–49(1, 40) = 4.9; p < 0.05]. Moreover, disease incidence was significantly lower in mice 
receiving TRAIL-deficient lymphocytes (EAE manifestation, i.e., a score of at least 1, was found in one out 
of seven mice), as compared to recipients of wild-type lymphocytes (EAE in 9 out of 11). Mean clinical 
disease scores with SEM are shown. 
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►Fig.4. TRAIL Inhibition Is Associated with Decreased Brain Cell Death in EAE 
(A) Brain cells expressing activated caspase 3 were identified by immunohistochemistry (amplified with 
ABC and visualized with HRP/DAB) in transverse brainstem sections from animals shown in ►Fig. 1B. 
Scale bars, 20 μm. Sections are from normal (left panel), Fc-treated (middle panel), or DR5:Fc-treated 
(right panel) mice, respectively. Arrows point to active caspase 3-positive cells. (B) Average number of 
oligodendrocytes and neurons positive for activated caspase 3 in brainstem sections. Each bar represents 
three mice from the vehicle (Fc)-treated and DR5:Fc-treated groups, with four sections analyzed per 
mouse (*p < 0.05, vehicle control-treated compared with DR5:Fc-treated animals, Mann-Whitney U test). 
Data show means with SEM. (C) Axonal pathology and areas of demyelination with bars representing five 
mice per group (means with SEM; *p < 0.05, Mann-Whitney U test). (D) Neuron from a control (Fc)-treated 
mouse exhibiting immunolabeling for activated caspase 3 (aCasp 3) throughout its cytoplasm, which was 
counterstained with hematoxylin. Arrows point to chromatin condensation indicating the final phase of 
apoptosis. (E) Ultrathin section and electron micrograph of apoptotic neuron exhibiting caspase 3 
immunolabeling (DAB; diffuse black precipitates) and morphologic characteristics of apoptosis, i.e., 
nuclear condensation (white arrowhead) and membrane blebbing (white arrow; insert). Scale bars, 2.5 
μm. (F) Light micrograph of TRAIL-expressing cells (dark blue/black signal reflecting DAB/Ni chromogen) 
in the vicinity of and in direct contact (arrowheads) with a brainstem neuron in the early phase of 
apoptosis exhibiting activated caspase 3 (aCasp 3) staining (brown signal reflecting DAB chromogen; 
arrows) in its cytoplasm. (G) Semithin section revealing that invading TRAIL-expressing cells show 
classical morphological characteristics of lymphocytes (arrowheads). The arrow points to a neighboring 
cell exhibiting morphological characteristics of macrophages. Scale bars (D, F, and G), 20 μm. 
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►Fig.5. Expression of TRAIL Receptor 2 in the CNS 
Brains from naive SJL mice were removed after perfusion with PBS (for RT-PCR and Western blot) or with 
4% PFA (for immunohistochemistry) and tested for the expression of the mouse TRAIL-R2. (A) TRAIL-R2 
mRNA expression in selected tissue samples assessed by RT-PCR. (B) TRAIL-R2 protein expression 
assessed by Western blot analysis using two different antibodies. (C and D) TRAIL-R2 expression analyzed 
by immunohistochemistry in the hippocampus (C) or brainstem (D) of the murine CNS. Arrows point to 
cells in the brainstem that are clearly positive. Scale bars, 50 μm. 
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►Fig.6. Selective TRAIL Susceptibility of the Inflamed CNS 
(A) Recombinant human TRAIL (rhTRAIL together with an enhancer antibody for multimerization; open 
squares) or enhancer antibody alone (filled squares) were injected intracisternally into healthy mice 
(arrowheads; n = 5). No clinical deficit was observed. (B and D) Results of quantitative gene expression 
analysis for TRAIL receptor 2 (B) and TRAIL (D) performed in different regions of the CNS (brainstem, 
spinal cord) from animals with active EAE (induced by immunization with PLP139-151; see Experimental 
Procedures for details) or from control animals (sham immunized, i.e., the same immunization protocol as 
used for active EAE, including pertussis toxin injections, but without PLP139-151). Animals were analyzed 
in the course of EAE, i.e., at day 3 (preclinical phase), at day 9 (disease manifestation), or at day 13 (disease 
peak) after immunization, respectively. Mean relative changes of gene expression assessed with real-time 
PCR are given (with SEM) and compared to sham immunized controls (**p < 0.01, Mann-Whitney U test). 
(C) Quantitative assessment of TRAIL-R2 protein expression on dentate granule cells in naive controls, Fc-
treated passive EAE, and DR5:Fc-treated passive EAE (disease peak for EAE animals). Four sections from 
four animals per group were analyzed. Results (mean + SEM) indicate TRAIL-R2 protein expression in 
relation to naive control animals (control = 100%) (*p < 0.05, **p < 0.01 for comparison with naive control 
group, respectively, Mann-Whitney U test). (E) Mild active EAE was significantly deteriorated by delivery 
of recombinant human TRAIL into the CNS prior to and at the onset of disease. SJL mice were immunized 
and treated with active rhTRAIL (400 ng per mouse) together with enhancer antibody for multimerization 
(n = 5; open squares; 2 μg per mouse) or enhancer antibody alone (n = 5; filled squares) intracisternally at 
days 6 and 8 after immunization [arrowheads; *F9–47(1, 20) = 6.7; p < 0.05 for comparison of mean clinical 
scores, ANOVA]. Mean clinical disease scores with SEM are given. (F) Distribution of recombinant human 
TRAIL throughout the brain and spinal cord was assessed 2, 6, and 12 hr following injection into the 
cisterna cerebello-medullaris. TRAIL was found distributed as far as the cortex and the spinal cord with a 
peak 6 hr following injection. Scale bars, 20 μm. 
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►Fig.7. DR5:Fc Protects from Encephalitogenic T Cell-Induced Brain Injury In Vitro 
(A) Propidium iodide-fluorescence microscopy of the SJL mouse living hippocampal brain slices without 
(left upper quadrant) or with the addition of PLP-specific encephalitogenic T cells (left lower quadrant, 
with Fc control). As a positive control, the hippocampus is shown in response to application of the 
neurotoxic agent NMDA (right upper quadrant). Cell death induced by encephalitogenic lymphocytes 
was reduced by soluble DR5:Fc (right lower quadrant). Scale bars, 100 μm. 
(B) The number of PI-positive cells was assessed in the neuronal cell layer of the slice culture incubated 
with culture medium alone, and with DR5:Fc or Fc, and with or without encephalitogenic T cells obtained 
from PLP-immunized SJL mice. An average number of 26 slices was analyzed per treatment group. 
Results (means + SEM) indicate cell counts in relation to nondamaged brain tissue (control = 1). The 
number of PI+ cells was significantly reduced upon incubation with soluble DR5:Fc (1 μg/ml), compared 
to Fc alone (1 μg/ml) or medium control (*p < 0.05, Mann-Whitney U test). 
(C) TRAIL mRNA expression was detected in MOG-specific T cells from wild-type animals but not in TRAIL-
deficient T cells. Number of PI-positive cells (means with SEM) is demonstrated in the neuronal cell layer 
of CA and DG after invasion of wild-type or TRAIL-deficient MOG-reactive lymphocytes (*p < 0.05, Mann-
Whitney U test). 
(D) With confocal laser scanning microscopy, TRAIL expression (blue) is demonstrated by fluorescence 
labeling of fixed and permeabilized encephalitogenic T cells using a wide pinhole and aperture for 
detection (left panel). After invasion into brain tissue (right panel), CFDA-labeled T cells (green) were 
found adjacent to dead PI-stained neuronal nuclei (red) surrounded and contacted by secreted TRAIL 
(blue). Areas without T cells and neurons do not contain any labeling for TRAIL (circles). Scale bars, 10 μm. 
